Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3).
David S. Mathai, Madeleine Cluck, Amna M. Aslam, Erin Amato, Arsalan Azam, Michael Banov, Kathleen A. Barrett, Carl J. Bonnett, David Feifel, Nicolas Grundmann, H. Samuel Ko, Rupert McShane, Sandhya Prashad, Tatiana Santini, Lowan H. Stewart, Patrick Sullivan, Stefany D. Wolfsohn, Jill O. Robinson, Amy L. Mcguire, L. Alison Mcinnes
J Affect Disord May 16, 2026 DOI: 10.1016/j.jad.2026.121970 via PubMed
Summary
AI-generated from the abstractA panel of experts from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners used a Delphi process to develop consensus guidelines for administering intravenous ketamine infusions to treat depressive disorders. The guidelines provide recommendations on patient selection, dosing, safety monitoring, and treatment protocols, aiming to standardize clinical practice and improve patient outcomes. The consensus reflects agreement among specialists on best practices for this off-label use of ketamine.
Study at a glance
| Characteristics | Consensus guidelines Peer reviewed |
|---|---|
| Population | Depressive disorders |
| Intervention | Intravenous ketamine infusions |
| Citations | 1 |
| Key finding | The guidelines establish expert consensus on the use of intravenous ketamine infusions for depressive disorders, covering patient selection, dosing, safety, and treatment protocols. |
Abstract
Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3).